Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
about
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast CancerERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancerMultiple gene aberrations and breast cancer: lessons from super-responders.A meta-analysis to evaluate the cellular processes regulated by the interactome of endogenous and over-expressed estrogen receptor alpha.Protective Effect of Piper aduncum Capsule on DMBA-induced Breast Cancer in Rats.High ERα36 Expression Level and Membrane Location Predict Poor Prognosis in Renal Cell Carcinoma.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancerDisruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cellsMiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Estrogen and progesterone receptors in breast cancer.Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.Cooperative Dynamics of AR and ER Activity in Breast Cancer.Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis.Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics.Analysis of HOX gene expression patterns in human breast cancer.Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
P2860
Q28383028-15C93A79-089A-4F83-BDD2-5D9C95A8B806Q33836140-5BEAB7A4-5042-4E7E-A470-4B8BB568BB0AQ34147910-62419676-987F-4B4A-A59C-70C5DBCD897EQ35049096-66D79EB0-8CC5-4BD8-9AF6-10CB08A8EA28Q35555115-78FED2F5-A1B6-4C6B-B8C5-0C538C909462Q35645466-A13302B7-A3E6-4676-B9AD-D5C410178C0DQ35745028-656B119D-1E0C-4D16-9888-633B03071DA7Q35811163-AB922029-1990-4AA1-B0C4-10256264DB5EQ35858096-51D5FBDD-A91B-438D-8135-C2091EC2C431Q36568006-5407166B-0AE1-41DE-A270-50A2413F2A5EQ37171068-1992EF32-4265-4AB5-BA3E-2AE5651CC002Q37641578-BEFE9C6C-F2A4-4074-AA1F-F4B3FA6C9F0EQ38105253-7CD1A430-115D-4B8B-AD29-9E885377B4F5Q38282467-C4F838B1-653A-446F-98B4-13B359A7EAF3Q38707608-A38272BE-F840-432F-A10D-0CDFA0693CC1Q38749913-E9716DE3-B08B-4FFC-9287-91F0E1E6E5BCQ39127733-4731AE35-1588-4781-8D3F-8F71CB8DD072Q41912547-FC6137B6-1088-44BE-B3A6-9986499CBAE9Q43957562-DBA8A6E0-AA37-4263-ADF0-947725FEAB36Q47850321-89CA3FD1-A932-4CB6-BEFE-2DF079D60F3FQ48342762-8CB2CD53-7F80-4AD7-B6FB-6A419E2AC491
P2860
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@en
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@nl
type
label
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@en
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@nl
prefLabel
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@en
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@nl
P2093
P1433
P1476
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
@en
P2093
C Kent Osborne
Mario Giuliano
Meghana V Trivedi
Rachel Schifp
P356
10.1016/S0960-9776(11)70293-4
P478
20 Suppl 3
P577
2011-10-01T00:00:00Z